Brought to you by 
ViroPharma gets rights to use Halozyme's Enhanze platform to deliver Cinryze; terminated
17 Dec 2014
Executive Summary
ViroPharma Inc.'s ViroPharma SPRL division (developing compounds for life-threatening diseases) has licensed exclusive global rights to Halozyme Therapeutics Inc.’s (uses enzymes to deliver drugs) Enhanze drug delivery platform, which contains the recombinant human hyaluronidase enzyme rHuPH20. ViroPharma will use the technology to create a single subcutaneous form of Cinryze (C1 esterase inhibitor (human)) for hereditary angioedema (HAE) as well as three other orphan conditions.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ViroPharma gets rights to use Halozyme's Enhanze platform to deliver Cinryze; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice